XML 146 R31.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisitions (Tables)
12 Months Ended
Sep. 30, 2019
Business Combinations [Abstract]  
Schedule of Recognized Assets Acquired and Liabilities Assumed The purchase price allocation was finalized during 2018 and the following table summarizes the values of the assets acquired and liabilities assumed at the date of acquisition.

 

 

 

At

 

 

 

May 17, 2017

 

Purchase price allocation (in millions)

 

As Adjusted

 

Assets:

 

 

 

 

Accounts receivable

 

 

52

 

Inventory

 

 

74

 

Other current assets

 

 

4

 

Intangible assets

 

 

330

 

Goodwill

 

 

288

 

Property, plant and equipment

 

 

94

 

Other noncurrent assets

 

 

17

 

Liabilities:

 

 

 

 

Accounts payable

 

 

(33

)

Deferred tax - net

 

 

(132

)

Other noncurrent liabilities

 

 

(14

)

Total purchase price

 

$

680

 

Schedule of Finite-Lived Intangible Assets as Part of Business Combination

The following details the total intangible assets identified as of May 17, 2017.

 

 

 

 

 

 

 

Weighted-average

 

 

 

 

 

 

 

amortization period

 

Intangible asset type (in millions)

 

Value

 

 

(years)

 

Trademarks and trade names

 

$

26

 

 

 

15

 

Intellectual property

 

 

68

 

 

 

22

 

Customer and supplier relationships

 

 

236

 

 

 

20

 

Total

 

$

330

 

 

 

 

 

Results of Operations The following table provides sales and operating income from the acquired Pharmachem operations included in Ashland’s 2017 results.

 

Pharmachem results of operations

 

 

 

 

(In millions)

 

2017 (a)

 

Sales

 

$

104

 

Operating income

 

 

7

 

 

 

 

 

 

(a)

Amounts represent the sales and results of operations for the period May 17, 2017 through September 30, 2017, the period for which Pharmachem was owned during 2017.

Business Acquisition, Pro Forma Information

The following unaudited pro forma information for 2017 assumes the acquisition of Pharmachem occurred at the beginning of the respective periods presented.

 

Unaudited pro forma information

 

 

 

 

(In millions)

 

2017

 

Sales

 

$

2,483

 

Net income

 

 

31